Background: The distinct expression pattern of tumour-associated antigens (TAAs) might be
a critical reason for the inefficacy of immunity-based treatments and heterogeneous …

Background Therapies targeting immune molecules have rapidly been adopted and
advanced the treatment of hepatocellular carcinoma (HCC). Nonetheless, no studies have …

Abstract Background Cancer-testis antigens (CTAs) and tumour-associated antigens (TAAs)
are frequently expressed in hepatocellular carcinoma (HCC); however, the role of tumour …

Aim We investigated whether tumor-specific CD8+ T-cell responses affect tumor-free
survival as well as the relationship between CD8+ T-cell responses against tumor …

Tumor-associated antigens (TAAs) recognized by cellular and/or humoral effectors of the
immune system are attractive targets for diagnostic and therapeutic approaches to human …

Background: The role of immune profiling and tumor budding in hepatocellular carcinoma
(HCC) remains largely unknown. This study evaluated the association between tumor …

Background Hepatocellular carcinoma (HCC) is one of the most prevalent and inflammation-
associated cancers. The tumor microenvironment (TME) plays an essential role in HCC …

Background Hepatocellular carcinoma (HCC) is prevalent worldwide and early diagnosis of
HCC is critical for effective treatment and optimal prognosis. Methods Serum was screened …

Background Hepatocellular carcinoma (HCC) has a poor prognosis and has become the
sixth most common malignancy worldwide due to its high incidence. Advanced approaches …

Hepatocellular carcinoma (HCC) is a deadly cancer with a 5-year survival of 18% for
patients at all stages.(1) Systemic treatments for advanced-stage HCC, including targeted …